HUP0202938A2 - N-aryl-2-sulfonamidobenzamides as phosphate transport inhibitors and pharmaceutical compositions containing them - Google Patents

N-aryl-2-sulfonamidobenzamides as phosphate transport inhibitors and pharmaceutical compositions containing them

Info

Publication number
HUP0202938A2
HUP0202938A2 HU0202938A HUP0202938A HUP0202938A2 HU P0202938 A2 HUP0202938 A2 HU P0202938A2 HU 0202938 A HU0202938 A HU 0202938A HU P0202938 A HUP0202938 A HU P0202938A HU P0202938 A2 HUP0202938 A2 HU P0202938A2
Authority
HU
Hungary
Prior art keywords
group
aryl
amino
carbamoyl
substituted
Prior art date
Application number
HU0202938A
Other languages
Hungarian (hu)
Inventor
Richard M. Edwards
Robert G. Franz
Dimitri Gaitanopoulos
Joseph Weinstock
Original Assignee
Smithkline Beecham Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp. filed Critical Smithkline Beecham Corp.
Publication of HUP0202938A2 publication Critical patent/HUP0202938A2/en
Publication of HUP0202938A3 publication Critical patent/HUP0202938A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems

Abstract

A találmány a nátriumfüggő foszfáttranszport inhibitorkéntalkalmazható (I) általános képletű vegyületekre vonatkozik, amelyekképletében R1 és R2 jelentése egymástól függetlenül hidrogénatom,alkil-, alkenil-, aralkil-, acil-, aril-karbonil-, halogén-alkil-,aril-, heteroarilcsoport, halogénatom, karboxi-, alkoxi-karbonil-,karbamoil-, alkil-karbamoil-, aril-karbamoil-, ciano-, alkoxi-,hidroxi-, fenil-azo-, amino-, nitro-, alkil-amino-, aril-amino-,aralkil-amino-, acil-amino-, (aril-karbonil)-amino-, alkil-tio-,aralkil-tio-, aril-tio-, alkil-szulfinil-, aril-szulfinil-, aralkil-szulfinil-, alkil-szulfonil-, aril-szulfonil-, aralkil- szulfonil-,szulfamoil-, (aril-szulfonil)-amino- vagy (alkil-szulfonil)- amino-csoport; vagy R1 és/vagy R2 az általa szubsztituált gyűrűvelbenzotiofént, naftalint, kinolint vagy izokinolint alkotó kondenzáltgyűrűt jelent; vagy (R1)n és/vagy (R2)m és az általa szubsztituáltgyűrű egy a következők közül kiválasztott heterociklust jelent:tiofén, furán, piridin, pirimidin és pirazin, valamintbenzoanalógjaik; és R3 jelentése alkil-, halogén-alkil-csoport, R1csoporttal szubsztituált arilcsoport vagy R1 csoporttal szubsztituáltaralkilcsoport, illetve egy R1 csoporttal szubsztituált heterociklusoscsoport, amely heterociklusos csoport a következő vegyületekbőlszármazik: tiofén, furán, piridin, pirimidin, pirazin, imidazol éstiazol, valamint benzoanalógjaik. A találmány kiterjed az (I)általános képletű vegyületeket tartalmazó gyógyszerkészítményekre,melyeket krónikus veseelégtelenség és urémiás csontbetegség kezelésérehasználnak. ÓThe invention relates to compounds of general formula (I) that can be used as sodium-dependent phosphate transport inhibitors, in which R1 and R2 are independently hydrogen atom, alkyl, alkenyl, aralkyl, acyl, arylcarbonyl, haloalkyl, aryl, heteroaryl, halogen atom, carboxy-, alkoxy-carbonyl-, carbamoyl-, alkyl-carbamoyl-, aryl-carbamoyl-, cyano-, alkoxy-, hydroxy-, phenylazo-, amino-, nitro-, alkylamino-, aryl- amino-, aralkylamino-, acylamino-, (arylcarbonyl)amino-, alkylthio-, aralkylthio-, arylthio-, alkylsulfinyl-, arylsulfinyl-, aralkylsulfinyl -, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, sulfamoyl, (arylsulfonyl)amino or (alkylsulfonyl)amino; or R1 and/or R2 represents a fused ring forming benzothiophene, naphthalene, quinoline or isoquinoline with the ring substituted by it; or (R1)n and/or (R2)m and the ring substituted by it represents a heterocycle selected from the following: thiophene, furan, pyridine, pyrimidine and pyrazine and their benzoanalogues; and R3 is an alkyl group, a haloalkyl group, an aryl group substituted with R1 group or a paraalkyl group substituted with R1 group, or a heterocyclic group substituted with R1 group, which heterocyclic group is derived from the following compounds: thiophene, furan, pyridine, pyrimidine, pyrazine, imidazole and thiazole, and their benzo analogues. The invention covers pharmaceutical preparations containing compounds of general formula (I), which are used for the treatment of chronic kidney failure and uremic bone disease. HE

HU0202938A 1999-07-20 2000-07-19 N-aryl-2-sulfonamidobenzamides as phosphate transport inhibitors and pharmaceutical compositions containing them HUP0202938A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14464699P 1999-07-20 1999-07-20
PCT/US2000/019616 WO2001005398A1 (en) 1999-07-20 2000-07-19 Phosphate transport inhibitors

Publications (2)

Publication Number Publication Date
HUP0202938A2 true HUP0202938A2 (en) 2003-01-28
HUP0202938A3 HUP0202938A3 (en) 2006-07-28

Family

ID=22509500

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202938A HUP0202938A3 (en) 1999-07-20 2000-07-19 N-aryl-2-sulfonamidobenzamides as phosphate transport inhibitors and pharmaceutical compositions containing them

Country Status (19)

Country Link
EP (1) EP1202729A1 (en)
JP (1) JP2003504403A (en)
KR (1) KR20020015382A (en)
CN (1) CN1361687A (en)
AR (1) AR030911A1 (en)
AU (1) AU6354300A (en)
BR (1) BR0012568A (en)
CA (1) CA2379657A1 (en)
CO (1) CO5190714A1 (en)
CZ (1) CZ2002204A3 (en)
HU (1) HUP0202938A3 (en)
IL (1) IL147697A0 (en)
MX (1) MXPA02000753A (en)
NO (1) NO20020278D0 (en)
NZ (1) NZ516619A (en)
PL (1) PL353741A1 (en)
TR (1) TR200200112T2 (en)
WO (1) WO2001005398A1 (en)
ZA (1) ZA200200464B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020093983A (en) * 2000-05-12 2002-12-16 스미스클라인 비참 코포레이션 Phosphate Transport Inhibitors
GB2378179A (en) * 2001-08-03 2003-02-05 Pantherix Ltd Aromatic sulfonamides and their use in treating bacterial diseases
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
WO2006047302A1 (en) 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
WO2006077901A1 (en) * 2005-01-20 2006-07-27 Shionogi & Co., Ltd. Ctgf expression inhibitor
CN102137669A (en) * 2008-06-03 2011-07-27 弗雷森纽斯医疗护理德国有限责任公司 Pharmaceutical compositions comprising gamma secretase modulators
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR101766619B1 (en) 2008-12-31 2017-08-08 알데릭스, 인코포레이티드 Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US8664425B2 (en) * 2010-02-02 2014-03-04 Honeywell International Inc. Bluegreen fluorescent compounds
JP5827326B2 (en) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting phosphate transport
JP5827327B2 (en) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting phosphate transport
JP5827328B2 (en) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting phosphate transport
JP5823514B2 (en) * 2010-07-07 2015-11-25 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting phosphate transport
EP2822935B1 (en) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
KR102138390B1 (en) 2012-08-21 2020-07-27 알데릭스, 인코포레이티드 Compounds and methods for inhibiting nhe-mediaded antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103183623A (en) * 2013-03-12 2013-07-03 中国医学科学院医药生物技术研究所 A group of benzene sulfonamido benzamide derivatives, and preparation and application thereof
EP2983667B1 (en) 2013-04-12 2019-03-20 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
CN105395532B (en) * 2015-11-25 2017-11-14 中国医学科学院医药生物技术研究所 Application of the 2 benzene sulfonamido benzamide compounds in liver injury protection and liver fibrosis preventing and treating
JP6713051B2 (en) 2016-08-30 2020-06-24 日本曹達株式会社 Sulfonylaminobenzamide compounds and pest control agents
AU2018206479B2 (en) 2017-01-09 2022-07-14 Ardelyx, Inc. Inhibitors of NHE-mediated antiport
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86462A (en) * 1987-05-29 1992-12-01 Fujisawa Pharmaceutical Co Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists

Also Published As

Publication number Publication date
HUP0202938A3 (en) 2006-07-28
PL353741A1 (en) 2003-12-01
KR20020015382A (en) 2002-02-27
MXPA02000753A (en) 2002-07-22
NO20020278L (en) 2002-01-18
NZ516619A (en) 2004-02-27
CN1361687A (en) 2002-07-31
BR0012568A (en) 2002-04-30
AU6354300A (en) 2001-02-05
JP2003504403A (en) 2003-02-04
CO5190714A1 (en) 2002-08-29
IL147697A0 (en) 2002-08-14
CZ2002204A3 (en) 2002-11-13
ZA200200464B (en) 2003-04-30
AR030911A1 (en) 2003-09-03
NO20020278D0 (en) 2002-01-18
CA2379657A1 (en) 2001-01-25
WO2001005398A1 (en) 2001-01-25
EP1202729A1 (en) 2002-05-08
TR200200112T2 (en) 2002-05-21

Similar Documents

Publication Publication Date Title
HUP0202938A2 (en) N-aryl-2-sulfonamidobenzamides as phosphate transport inhibitors and pharmaceutical compositions containing them
HUP0300195A2 (en) Heterocyclic sodium/proton exchange inhibitors and pharmaceutical compositions containing them
DOP2006000063A (en) CYCLOPROPANOCARBOXAMIDE DERIVATIVES
HUP0302234A2 (en) Phosphate transport inhibitors, pharmaceutical compositions containing them and their use
HUP0001243A2 (en) Nicotinamide derivatives and pharmaceutical compositions containing them
HUP0402352A2 (en) Pyrimidine derivatives for use as phosphodiesterase (pde)7 inhibitors and pharmaceutical compositions containing them
MX9700308A (en) Heterobicyclic derivatives.
PT1251848E (en) GELASE INHIBITORS AND THEIR UTILIZATIONS
HUP0202001A2 (en) Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
EA200200708A1 (en) Derivatives of benzene and their use as modulators of JNK
HUP0002353A2 (en) 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phoshodiesterase iv inhibitory activity and pharmaceutical compositions containing them
DK0958296T3 (en) Heterocyclic Compounds, Methods of Preparation and Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes and Related Diseases
HUP0400828A2 (en) Fused heterocyclic aminopyrimidines, their use and pharmaceutical compositions containing them
MX2007000016A (en) Pyrazole derivatives.
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
HUP0001507A2 (en) Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
CY1106358T1 (en) NEW BICYCLIC INHIBITORS OF HORMONE-SENSITIVE LIPASE
ID27535A (en) PIRASOLA DURATION AS P-38 MAP KINASE INHIBITOR
HRP20041137B1 (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
NO20053133L (en) Chemical connections.
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
BR112017022654A2 (en) 6-membered heterocyclic derivative and pharmaceutical composition comprising the same
HUP0300427A2 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain, process for their preparation and pharmaceutical compositions containing them
HUP0301341A2 (en) Piperidine derivatives of ccr-3 inhibitors, process for their preparation and pharmaceutical compositions containing them
CY1114927T1 (en) NEW 2-SUBSTITUTED PENAMY METHOD PRODUCERS

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished